Clinical Trial Update: BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Withdrawn Phase 1/2 clinical trial of BC3402 in combination with tremelimumab and durvalumab (STRIDE) for hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• BC3402
• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Hepato Cellular Carcinoma (HCC) | Phase 1, Phase 2 | Status: WITHDRAWN